Whitehawk Therapeutics, Inc. (WHWK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Whitehawk Therapeutics Inc WHWK
$3.74
▼ -3.11%
($-0.12)
⬇️ Below Yest. Low
Open
$3.85
Prev Close
$3.86
Day Range
$3.74 – $3.89
52W Range
$1.82 – $5.50
Market Cap
$207.07M
Beta
1.00
EPS (TTM)
$-3.03
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2018-06-26 |
| Shares Out. | 53,780,000 |
| Website | ir.whitehawktx.com/ ↗ |
| Phone | 15513212234 |
| Employees | 23 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$16.6M |
| Free Cash Flow | -$69.3M |
| Total Assets | $194.0M |
| Total Liabilities | $11.1M |
| Equity | $182.9M |
About Whitehawk Therapeutics Inc
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.
Whitehawk Therapeutics Inc is a publicly traded company under the ticker symbol WHWK on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
14 analysts (2026-09-01)
📰 Latest News for WHWK
Reported Sunday, Whitehawk's Real-World Data Show PTK7 Expression Remains Stable After Standard-Of-Care Therapies, Reinforcing Rationale For HWK-007 In EGFR Wild-Type NSCLC
Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026